新发糖尿病亚组中糖尿病相关疾病风险的5年随访研究
该研究基于德国糖尿病研究对1105例新发1型或2型糖尿病患者进行基线聚类分析及5年随访,分为5个亚组。结果显示SIRD组全身胰岛素敏感性最低且肝脂肪含量最高,随访时肝纤维化更常见;SIDD组基线确诊糖尿病周围神经病变更普遍。提示特定糖尿病亚组在非酒精性脂肪性肝病和糖尿病神经病变早期即表现出不同并发症患病率。
要点
- 5年随访时SIRD组肝纤维化患病率(26%)高于SAID、MARD、MOD和SIDD组。
- 基线时SIDD组确诊糖尿病感觉运动多神经病变患病率(36%)高于其他亚组。
核心结论
- 聚类分析可区分全身及脂肪组织胰岛素抵抗程度不同的队列,特定糖尿病亚组在非酒精性脂肪性肝病和糖尿病神经病变早期阶段表现出不同的并发症患病率。
研究设计与样本
- 德国糖尿病研究(German Diabetes Study)纳入新诊断1型或2型糖尿病患者,基线进行综合表型评估和实验室变量检测,5年后重新评估。
- 基线共1105例患者被分为5个聚类:MARD 386例(35%)、MOD 323例(29%)、SAID 247例(22%)、SIRD 121例(11%)、SIDD 28例(3%)。
- 5年随访时367例患者被重新评估:MARD 128例(35%)、MOD 106例(29%)、SAID 88例(24%)、SIRD 35例(10%)、SIDD 10例(3%)。
临床怎么用
- 对SIRD亚组患者应关注非酒精性脂肪性肝病及肝纤维化风险,早期评估和干预。
- 对SIDD亚组患者应关注糖尿病周围神经病变的早期筛查。
- 基于聚类分型的精准分型有助于制定针对性的并发症预防和治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cluster analyses have proposed different diabetes phenotypes using age, BMI, glycaemia, homoeostasis model estimates, and islet autoantibodies. We tested whether comprehensive phenotyping validates and further characterises these clusters at diagnosis and whether relevant diabetes-related complications differ among these clusters, during 5-years of follow-up. METHODS: Patients with newly diagnosed type 1 or type 2 diabetes in the German Diabetes Study underwent comprehensive phenotyping and assessment of laboratory variables. Insulin sensitivity was assessed using hyperinsulinaemic-euglycaemic clamps, hepatocellular lipid content using magnetic resonance spectroscopy, hepatic fibrosis using non-invasive scores, and peripheral and autonomic neuropathy using functional and clinical criteria. Patients were reassessed after 5 years. The German Diabetes Study is registered with ClinicalTrials.gov, number NCT01055093, and is ongoing. FINDINGS: 1105 patients were classified at baseline into five clusters, with 386 (35%) assigned to mild age-related diabetes (MARD), 323 (29%) to mild obesity-related diabetes (MOD), 247 (22%) to severe autoimmune diabetes (SAID), 121 (11%) to severe insulin-resistant diabetes (SIRD), and 28 (3%) to severe insulin-deficient diabetes (SIDD). At 5-year follow-up, 367 patients were reassessed, 128 (35%) with MARD, 106 (29%) with MOD, 88 (24%) with SAID, 35 (10%) with SIRD, and ten (3%) with SIDD. Whole-body insulin sensitivity was lowest in patients with SIRD at baseline (mean 4·3 mg/kg per min [SD 2·0]) compared with those with SAID (8·4 mg/kg per min [3·2]; p<0·0001), MARD (7·5 mg/kg per min [2·5]; p<0·0001), MOD (6·6 mg/kg per min [2·6]; p=0·0011), and SIDD (5·5 mg/kg per min [2·4]; p=0·0035). The fasting adipose-tissue insulin resistance index at baseline was highest in patients with SIRD (median 15·6 [IQR 9·3-20·9]) and MOD (11·6 [7·4-17·9]) compared with those with MARD (6·0 [3·9-10·3]; both p<0·0001) and SAID (6·0 [3·0-9·5]; both p<0·0001). In patients with newly diagnosed diabetes, hepatocellular lipid content was highest at baseline in patients assigned to the SIRD cluster (median 19% [IQR 11-22]) compared with all other clusters (7% [2-15] for MOD, p=0·00052; 5% [2-11] for MARD, p<0·0001; 2% [0-13] for SIDD, p=0·0083; and 1% [0-3] for SAID, p<0·0001), even after adjustments for baseline medication. Accordingly, hepatic fibrosis at 5-year follow-up was more prevalent in patients with SIRD (n=7 [26%]) than in patients with SAID (n=5 [7%], p=0·0011), MARD (n=12 [12%], p=0·012), MOD (n=13 [15%], p=0·050), and SIDD (n=0 [0%], p value not available). Confirmed diabetic sensorimotor polyneuropathy was more prevalent at baseline in patients with SIDD (n=9 [36%]) compared with patients with SAID (n=10 [5%], p<0·0001), MARD (n=39 [15%], p=0·00066), MOD (n=26 [11%], p<0·0001), and SIRD (n=10 [17%], p<0·0001). INTERPRETATION: Cluster analysis can characterise cohorts with different degrees of whole-body and adipose-tissue insulin resistance. Specific diabetes clusters show different prevalence of diabetes complications at early stages of non-alcoholic fatty liver disease and diabetic neuropathy. These findings could help improve targeted prevention and treatment and enable precision medicine for diabetes and its comorbidities. FUNDING: German Diabetes Center, German Federal Ministry of Health, Ministry of Culture and Science of the state of North Rhine-Westphalia, German Federal Ministry of Education and Research, German Diabetes Association, German Center for Diabetes Research, Research Network SFB 1116 of the German Research Foundation, and Schmutzler Stiftung.
引用
- Zaharia OP, Strassburger K, Strom A, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol. 2019. PMID: 31345776. doi:10.1016/S2213-8587(19)30187-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。